NEXT LEVEL PRODUCTS
NEXT LEVEL SERVICE.
How are new genetics made?
It all begins with an idea. Maybe you want to create a new Sativa, or an Indica hybrid strain or you’re just curious how it’s done, possibilities with breeding are endless but we will talk about the simple but most important things breeders look for when selecting plants to breed, this information is brought to you by one of the most notorious growers out of Humboldt.
DID IT JUST GET CHEAPER?
Due to recent changes in legislation set to take effect on June 6, 2024, medical patients in Washington State can expect to pay significantly less for cannabis products. The new law allows medically endorsed dispensaries to exempt qualifying medical patients from the Excise Tax on Department of Health (DOH)-compliant products. To benefit from this exemption, several conditions must be met: the dispensing facility must hold a valid medical endorsement, the patient must present a valid medical card, and the cannabis product must be approved as DOH-compliant. This initiative aims to promote accessible healthcare alternatives for patients managing various medical conditions, ultimately lowering their overall expenditure on cannabis while ensuring the integrity and safety of the products they purchase.
New Tax Exemption for Medical Cannabis in Washington: A Win for Patients, A Hurdle for Businesses
As of June 6, 2024, Washington State’s new legislation exempts qualifying medical cannabis patients from the Excise Tax on DOH-compliant products—a move celebrated by many for making medical cannabis more accessible and affordable. However, while patients benefit, the implementation is far more complicated—and costly—for producers and retailers.
Patient Perks:
No Excise Tax on approved products.
Encourages use of DOH-compliant, safer, lab-tested cannabis.
Greater affordability for long-term treatment options.
Business Burdens:
Medical Endorsement Required: Farms and dispensaries must obtain and maintain a medical endorsement, which requires navigating a complex application process and stricter operational standards.
Higher Compliance Costs: Products must meet rigorous DOH standards, often requiring additional testing, labeling, and processing—raising production costs.
Limited Market Incentive: While businesses front the costs, the patient pool is relatively small, and margins shrink significantly when tax is removed from transactions.
Tax Trade-Offs: Ironically, while patients are exempt from the Excise Tax, businesses still pay B&O taxes and increased compliance-related expenses, making it difficult to break even—let alone profit—from medical sales.
In short, while the legislation is a positive step for patient access, it's a double-edged sword for cannabis businesses, who may find themselves spending more to participate in the program than they make back in sales. The challenge lies in balancing compassion with sustainability.
CHECK OUT THE NEW HIDDEN BUSH SONG